Cargando…
Mild Cognitive Impairment with a High Risk of Progression to Alzheimer’s Disease Dementia (MCI-HR-AD): Effect of Souvenaid(®) Treatment on Cognition and (18)F-FDG PET Scans
BACKGROUND: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer’s disease (AD) and mild cognitive impairment (MCI). OBJECTIVE: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegene...
Autores principales: | Manzano Palomo, Maria Sagrario, Anaya Caravaca, Belen, Balsa Bretón, Maria Angeles, Castrillo, Sergio Muñiz, Vicente, Asuncion de la Morena, Castro Arce, Eduardo, Alves Prez, María Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597964/ https://www.ncbi.nlm.nih.gov/pubmed/31259306 http://dx.doi.org/10.3233/ADR-190109 |
Ejemplares similares
-
Souvenaid in the management of mild cognitive impairment: an expert consensus opinion
por: Cummings, Jeffrey, et al.
Publicado: (2019) -
Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study
por: Teng, Lirong, et al.
Publicado: (2020) -
Efficacy of Souvenaid(®) Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer’s Disease
por: García-Alberca, José María, et al.
Publicado: (2023) -
Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease
por: Cummings, Jeffrey, et al.
Publicado: (2016) -
Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)